A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Public ClinicalTrials.gov record NCT00130676. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of CORLUX™ (Mifepristone) in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this 56 day study is to learn the safety and effectiveness of Corlux in patients who have been diagnosed with psychotic major depression (PMD).
Study identification
- NCT ID
- NCT00130676
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 257 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2004
- Primary completion
- May 31, 2006
- Completion
- May 31, 2006
- Last update posted
- Feb 14, 2012
2004 – 2006
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CNRI-LA | Pico Rivera | California | 90660 | — |
| Behavioral Health 2000, LLC | Riverside | California | 92506 | — |
| Cnri, Llc | San Diego | California | 92126 | — |
| University of Florida Clinical Trials | Jacksonville | Florida | 32257 | — |
| Quantum Laboratories/Memory Disorder Center | Pompano Beach | Florida | 33064 | — |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30308 | — |
| American Medical Research, Inc. | Oak Brook | Illinois | 60523 | — |
| Valle Vista Health System | Greenwood | Indiana | 46143 | — |
| Psychopharmacology Research | Farmington Hills | Michigan | 48334 | — |
| Robert Horne, MD | Las Vegas | Nevada | 89102 | — |
| CNS Research Institute | Clementon | New Jersey | 08021 | — |
| NMDNJ | Newark | New Jersey | 07101 | — |
| Bio Behavioral Health | Toms River | New Jersey | 08755 | — |
| Zucker Hillside Hospital | Glen Oaks | New York | 11004 | — |
| Neurobehavioral Research Company | Lawrence | New York | 11559 | — |
| Midwest Clinical Research Center | Dayton | Ohio | 45408 | — |
| Rakesh Ranjan, MD and Associates, Inc | Lyndhurst | Ohio | 44124 | — |
| IPS Research Company | Oklahoma City | Oklahoma | 73101 | — |
| CNS Research Institute | Philadelphia | Pennsylvania | 19149 | — |
| Claghorn-Lesem Research Clinic | Bellaire | Texas | 77401 | — |
| Grayline Clinical Drug Trials | Wichita Falls | Texas | 76309 | — |
| International Clinical Research Associates | Richmond | Virginia | 23229 | — |
| Northwest Clinical Research Center | Bellevue | Washington | 98004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00130676, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 14, 2012 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00130676 live on ClinicalTrials.gov.